ASH 2022: 1529: Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies
Download pdf 232KB
View External Link
- Categories
- Posters
- Topics:
- B-cell lymphoma
- DLBCL
- Tislelizumab
- TME
- Zanubrutinlb